Janux Therapeutics, Inc. Operating Income
Janux Therapeutics, Inc. (JANX) reported Operating Income of -$31.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Janux Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$31.69M.
- Janux Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$34.21M.
- Janux Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$42.40M.
- Janux Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$35.25M.
- Janux Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$157.67M.
- Janux Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$98.85M.
- Janux Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$72.98M.
- Janux Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$67.09M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.69M 10-Q · filed 2026-08-06 | -$65.90M 10-Q · filed 2026-08-06 | -$108.30M derived: sum of 3 quarters · filed 2026-08-06 | -$143.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$34.21M 10-Q · filed 2026-05-07 | -$76.61M derived: sum of 2 quarters · filed 2026-05-07 | -$111.86M derived: sum of 3 quarters · filed 2026-05-07 | -$156.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$42.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$77.65M derived: sum of 2 quarters · filed 2026-02-26 | -$122.77M derived: sum of 3 quarters · filed 2026-08-06 | -$157.67M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$35.25M 10-Q · filed 2025-11-06 | -$80.37M derived: sum of 2 quarters · filed 2026-08-06 | -$115.27M 10-Q · filed 2025-11-06 | -$144.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$45.12M 10-Q · filed 2026-08-06 | -$80.02M 10-Q · filed 2026-08-06 | -$109.04M derived: sum of 3 quarters · filed 2026-08-06 | -$144.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$34.90M 10-Q · filed 2026-05-07 | -$63.92M derived: sum of 2 quarters · filed 2026-05-07 | -$99.76M derived: sum of 3 quarters · filed 2026-05-07 | -$113.58M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$29.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$64.86M derived: sum of 2 quarters · filed 2026-02-26 | -$78.69M derived: sum of 3 quarters · filed 2026-02-26 | -$98.85M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$35.84M 10-Q · filed 2025-11-06 | -$49.66M derived: sum of 2 quarters · filed 2025-11-06 | -$69.83M 10-Q · filed 2025-11-06 | -$85.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$13.82M 10-Q · filed 2025-08-07 | -$33.98M 10-Q · filed 2025-08-07 | -$50.12M derived: sum of 3 quarters · filed 2026-02-26 | -$65.93M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$20.16M 10-Q · filed 2025-05-08 | -$36.30M derived: sum of 2 quarters · filed 2026-02-26 | -$52.11M derived: sum of 3 quarters · filed 2026-02-26 | -$72.86M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$16.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$31.95M derived: sum of 2 quarters · filed 2026-02-26 | -$52.70M derived: sum of 3 quarters · filed 2026-02-26 | -$72.98M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$15.81M 10-Q · filed 2024-11-06 | -$36.56M derived: sum of 2 quarters · filed 2024-11-06 | -$56.84M 10-Q · filed 2024-11-06 | -$75.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$20.75M 10-Q · filed 2024-08-07 | -$41.03M 10-Q · filed 2024-08-07 | -$59.30M derived: sum of 3 quarters · filed 2025-02-27 | -$77.32M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$20.28M 10-Q · filed 2024-05-08 | -$38.55M derived: sum of 2 quarters · filed 2025-02-27 | -$56.57M derived: sum of 3 quarters · filed 2025-02-27 | -$73.83M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$36.29M derived: sum of 2 quarters · filed 2025-02-27 | -$53.55M derived: sum of 3 quarters · filed 2025-02-27 | -$67.09M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$18.02M 10-Q · filed 2023-11-07 | -$35.28M derived: sum of 2 quarters · filed 2023-11-07 | -$48.83M 10-Q · filed 2023-11-07 | -$62.31M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$17.26M 10-Q · filed 2023-08-08 | -$30.80M 10-Q · filed 2023-08-08 | -$44.29M derived: sum of 3 quarters · filed 2023-08-08 | -$55.20M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$13.54M 10-Q · filed 2023-05-09 | -$27.03M derived: sum of 2 quarters · filed 2023-05-09 | -$37.94M derived: sum of 3 quarters · filed 2023-05-09 | -$44.19M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$13.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$24.39M derived: sum of 2 quarters · filed 2023-03-10 | -$30.64M derived: sum of 3 quarters · filed 2023-03-10 | -$32.93M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$10.90M 10-Q · filed 2022-11-10 | -$17.16M derived: sum of 2 quarters · filed 2022-11-10 | -$19.44M 10-Q · filed 2022-11-10 | -$21.09M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$6.25M 10-Q · filed 2022-08-09 | -$8.54M 10-Q · filed 2022-08-09 | -$10.19M derived: sum of 3 quarters · filed 2022-08-09 | -$11.45M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$2.28M 10-Q · filed 2022-05-10 | -$3.94M derived: sum of 2 quarters · filed 2022-05-10 | -$5.20M derived: sum of 3 quarters · filed 2022-05-10 | -$6.30M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$2.91M derived: sum of 2 quarters · filed 2022-03-18 | -$4.02M derived: sum of 3 quarters · filed 2022-03-18 | -$4.84M 10-K · filed 2022-03-18 |
| 2020-09-30 | -$1.26M 10-Q · filed 2021-11-09 | -$2.36M derived: sum of 2 quarters · filed 2021-11-09 | -$3.19M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$1.11M 10-Q · filed 2021-08-10 | -$1.93M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |